+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

From
From
From
IgA Nephropathy (IgAN) - Epidemiology Forecast - 2032 - Product Thumbnail Image

IgA Nephropathy (IgAN) - Epidemiology Forecast - 2032

  • Report
  • July 2023
  • 100 Pages
  • Global
From
From
From
From
From
From
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2024 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
From
Diabetic Nephropathy - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Nephropathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Chronic Kidney Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Kidney Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Complement 3 Glomerulopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Complement 3 Glomerulopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Autoimmune Hepatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Autoimmune Hepatitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024 - Product Thumbnail Image

Autosomal dominant polycystic kidney disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 75 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more